Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
ANIK compared with VRCA: revenue, margins and what each company keeps, and the suppliers and customers both name
ANIK
Anika Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
VRCA
Verrica Pharmaceuticals Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
ANIK
Anika Therapeutics, Inc.
vs
VRCA
Verrica Pharmaceuticals Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
ANIK, solid
VRCA, dashed
Supply-chain overlap
Revenue flow
VRCA: latest quarter is a loss; flow not drawable.
Method
›
ANIK
Anika Therapeutics, Inc.
Change
20.98
▼
−3.72%
· post 20.64
Mkt cap
$280.4M
Revenue
$33M
Q2 FY26
Revenue
$113M
FY25
VRCA
Verrica Pharmaceuticals Inc.
Change
3.30
▼
−3.51%
· post 3.40
Closed
Oct 30 '26
Mkt cap
$57.5M
Revenue
$6M
Q2 FY26
Revenue
$36M
FY25
vs
Compare
Closed
Oct 30 '26
ANIK
Anika Therapeutics, Inc.
vs
VRCA
Verrica Pharmaceuticals Inc.
20.98
▼
−3.72%
post 20.64
Price
3.30
▼
−3.51%
post 3.40
$280.4M
Mkt cap
$57.5M
Q2 FY26
$33M
Revenue
$6M
Q2 FY26
FY25
$113M
Revenue
$36M
FY25
Change
Change
ANIK
20.98
▼
−3.72%
vs
VRCA
3.30
▼
−3.51%
Closed
Oct 30 '26
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only ANIK
1
JNJ
Johnson & Johnson MedTech
customer
Shared
0
No shared counterparties.
Only VRCA
1
—
Lytix BioPharma AS
unlisted
supplier
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR